Clinical Trials · NCT00234572
Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
- Phase
- Phase 2/Phase 3
- Recruitment status
- Completed
- Sponsor
- Ipsen
- Enrollment
- 108
- Start date
- May 2000
- Locations
- 29 sites, 8 countries
- Primary endpoint
- Mean serum GH levels determined from serial measurements at screening, weeks 4, 13, 14, 15, 16, 32 & 52, and in the event of early withdrawal